Background: Cisplatin, etoposide and irinotecan are primary drugs in the treatment of small cell lung cancer. We did this retrospective study to investigate whether combined chemotherapy with cisplatin, etoposide, and irinotecan was better than topotecan alone as second-line chemotherapy in patients with sensitive relapsed SCLC. Method: Between 1st Sep, 2014 and 30th Sep, 2017，We collected the patients information in Jilin Province Cancer Hospital. All patients with SCLC responded in first-line treatment and showed radiological evidence of disease relapse or progression at least 90 days after completion of the first-line treatment. 36 patients received combination chemotherapy with cisplatin plus etoposide plus irinotecan and 42 patients received topotecan alone. Combination chemotherapy consisted of five 2-week courses of intravenous cisplatin 25 mg/m 2 on days 1 and 8, intravenous etoposide 60 mg/m 2 on days 1e3, and intravenous irinotecan 90 mg/m 2 on day 8. Topotecan therapy consisted of four courses of intravenous topotecan 1.0 mg/m 2 on days 1e5, every 3 weeks. The primary endpoint was overall survival, which was analysed with a onesided a of 5%, and safety was assessed in all patients who received at least one dose of drugs. Results: The median follow-up for patients was 20.6 months (IQR 17.1e26.9). Overall survival was significantly longer in the combination chemotherapy group (median 16.3 months, 95% CI 13.8e19.1) than in the topotecan group (13.1 months, 10.2e15.4; hazard ratio 0.72, 90% CI 0.58e0.83; p¼0.0097). The most common grade 3/4 adverse events were neutropenia (31 [86.1%] Background: EGFR-based targeted therapy improves the survival of patients with advanced lung adenocarcinoma harboring EGFR mutations. However, factors including treatment or heterogeneity contribute partly to EGFR genetic status alteration between baseline and disease progresses (PD). The aim of the study is to compare difference of EGFR mutations between biopsy and rebiopsy in real world. Method: Data from 61 paired specimens performed EGFR testing in Jilin Provincial Cancer Hospital between January 2015 and December 2017 were collected and analyzed. The specimens were collected at baseline and PD, confirmed by histology or cytology and categorized as tumor tissue, malignant pleural effusion or plasma. All patients were naive and received chemotherapy or targeted therapy as first-line treatment. Amplification Refractory Mutation System (ARMS) was used to detect EGFR mutations. Results: EGFR mutation rate in tumor tissue, pleural effusion or blood was 90.2% vs 88.5%, 6.6% vs 6.6% and 3.2% vs 4.9% at baseline or PD respectively and discrepancy was 72% and 36.3% for the same (n¼50) or different (n¼11) type of specimens. The EGFR mutation rate was 95.1% and91.8% in patients before and after treatment, and the discrepancy was63.9%, among which, 69.2% and 92.3% in chemotherapy-treated patients (n¼ 13) with discrepancy to 46.1%（6/13), and 100% and 91.7% in EGFR-TKI-treated patients (n¼48) with discrepancy to 70.8%. There were four types of alterations in terms of EGFR mutations: wild type turned into mutation (4.9%), mutation disappeared (8.2%), sensitive mutations transformed (1.6%), and new mutations appeared (49.1%). Conclusion: In real world, the EGFR mutation status in advanced NSCLC patients altered significantly, due to tissue resources and therapeutic approaches, implying the importance of rebiopsy and real-time detection of EGFR mutation, in order to provide data to guide precise strategy in the following treatment.
Background: Cisplatin, etoposide and irinotecan are primary drugs in the treatment of small cell lung cancer. We did this retrospective study to investigate whether combined chemotherapy with cisplatin, etoposide, and irinotecan was better than topotecan alone as second-line chemotherapy in patients with sensitive relapsed SCLC. Method: Between 1st Sep, 2014 and 30th Sep, 2017，We collected the patients information in Jilin Province Cancer Hospital. All patients with SCLC responded in first-line treatment and showed radiological evidence of disease relapse or progression at least 90 days after completion of the first-line treatment. 36 patients received combination chemotherapy with cisplatin plus etoposide plus irinotecan and 42 patients received topotecan alone. Combination chemotherapy consisted of five 2-week courses of intravenous cisplatin 25 mg/m 2 on days 1 and 8, intravenous etoposide 60 mg/m 2 on days 1e3, and intravenous irinotecan 90 mg/m 2 on day 8. Topotecan therapy consisted of four courses of intravenous topotecan 1.0 mg/m 2 on days 1e5, every 3 weeks. The primary endpoint was overall survival, which was analysed with a onesided a of 5%, and safety was assessed in all patients who received at least one dose of drugs. Results: The median follow-up for patients was 20.6 months (IQR 17.1e26.9 Background: EGFR-based targeted therapy improves the survival of patients with advanced lung adenocarcinoma harboring EGFR mutations. However, factors including treatment or heterogeneity contribute partly to EGFR genetic status alteration between baseline and disease progresses (PD). The aim of the study is to compare difference of EGFR mutations between biopsy and rebiopsy in real world. Method: Data from 61 paired specimens performed EGFR testing in Jilin Provincial Cancer Hospital between January 2015 and December 2017 were collected and analyzed. The specimens were collected at baseline and PD, confirmed by histology or cytology and categorized as tumor tissue, malignant pleural effusion or plasma. All patients were naive and received chemotherapy or targeted therapy as first-line treatment. Amplification Refractory Mutation System (ARMS) was used to detect EGFR mutations. Results: EGFR mutation rate in tumor tissue, pleural effusion or blood was 90.2% vs 88.5%, 6.6% vs 6.6% and 3.2% vs 4.9% at baseline or PD respectively and discrepancy was 72% and 36.3% for the same (n¼50) or different (n¼11) type of specimens. The EGFR mutation rate was 95.1% and91.8% in patients before and after treatment, and the discrepancy was63.9%, among which, 69.2% and 92.3% in chemotherapy-treated patients (n¼ 13) with discrepancy to 46.1%（6/13), and 100% and 91.7% in EGFR-TKI-treated patients (n¼48) with discrepancy to 70.8%. There were four types of alterations in terms of EGFR mutations: wild type turned into mutation (4.9%), mutation disappeared (8.2%), sensitive mutations transformed (1.6%), and new mutations appeared (49.1%). Conclusion: In real world, the EGFR mutation status in advanced NSCLC patients altered significantly, due to tissue resources and therapeutic approaches, implying the importance of rebiopsy and real-time detection of EGFR mutation, in order to provide data to guide precise strategy in the following treatment. 
